Voleon Capital Management LP Invests $1.21 Million in Moderna, Inc. $MRNA

Key Points

• Voleon Capital Management LP has invested approximately $1.21 million in Moderna, acquiring 42,507 shares in the company's stock during the first quarter.
• Institutional investors and hedge funds collectively own 75.33% of Moderna's stock, reflecting increasing confidence among major shareholders.
• Recent earnings revealed a loss of ($2.13) EPS for the quarter, surpassing estimates, with revenue down 41.1% compared to the previous year.

Voleon Capital Management LP acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 42,507 shares of the company's stock, valued at approximately $1,205,000.

Several other hedge funds have also bought and sold shares of the business. Theleme Partners LLP grew its position in Moderna by 1.0% in the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company's stock valued at $303,819,000 after purchasing an additional 72,028 shares during the period. Invesco Ltd. grew its position in Moderna by 17.5% in the 1st quarter. Invesco Ltd. now owns 5,883,624 shares of the company's stock valued at $166,801,000 after purchasing an additional 877,162 shares during the period. Northern Trust Corp boosted its holdings in Moderna by 5.4% during the 1st quarter. Northern Trust Corp now owns 3,119,626 shares of the company's stock worth $88,441,000 after acquiring an additional 160,572 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Moderna by 12.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company's stock worth $74,557,000 after acquiring an additional 285,662 shares during the last quarter. Finally, Voloridge Investment Management LLC boosted its holdings in Moderna by 335.6% during the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company's stock worth $107,727,000 after acquiring an additional 1,996,003 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on MRNA. Bank of America lowered their target price on Moderna from $26.00 to $25.00 and set an "underperform" rating on the stock in a research note on Tuesday, July 22nd. Morgan Stanley reissued an "equal weight" rating and set a $32.00 price objective on shares of Moderna in a report on Friday, August 1st. JPMorgan Chase & Co. set a $26.00 price objective on Moderna in a report on Friday, August 1st. William Blair reaffirmed a "market perform" rating on shares of Moderna in a research note on Monday, June 2nd. Finally, Evercore ISI set a $32.00 target price on Moderna in a research note on Friday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, sixteen have assigned a Hold rating and four have issued a Sell rating to the company. According to MarketBeat.com, Moderna presently has an average rating of "Hold" and a consensus price target of $42.88.

Moderna Stock Performance

Shares of NASDAQ:MRNA opened at $24.83 on Tuesday. The stock has a market capitalization of $9.66 billion, a price-to-earnings ratio of -3.30 and a beta of 1.93. The stock's 50-day simple moving average is $28.79 and its two-hundred day simple moving average is $28.39. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $79.96.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings data on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping the consensus estimate of ($2.99) by $0.86. The firm had revenue of $142.00 million for the quarter, compared to the consensus estimate of $116.26 million. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The business's revenue for the quarter was down 41.1% compared to the same quarter last year. During the same quarter last year, the company earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. As a group, equities analysts forecast that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.